first patented BACE1 protease inhib. of series

Ph. II/III in Alzheimer’s, discontinued (tox.)

from phenotypic screen and SBDD

J. Med. Chem., Feb. 15, 2021

Shionogi Pharmaceutical, Osaka, JP


9. The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: